Patient Engagement for the Life Sciences
September 12, 2018 | Patient-centric, Patient-centricity, life sciences, patient engagement
Patient Engagement for the Life Sciences, written by Guy Yeoman and Mitchell Silva with editorial and design support from Cuttsy+Cuttsy, explains the ‘why’ and the ‘how’ of patient engagement. It presents the compelling argument for why life science companies need to embrace and partner with patients and outlining an operating framework for doing it effectively.
Visit www.medipace.com/book to download your copy.
We’re really proud to have been working with Guy Yeoman and Mitch Silva on their new book, Patient Engagement for the Life Sciences. To celebrate the book launch, we’ve been talking to Guy about why patient engagement is so important to pharma. I’m a firm believer and I’m passionate about effective patient engagement. I think it delivers value for the industry, but also for patients and society at large. My background is in the pharmaceutical business. I’ve been working for the last two decades in the industry, and over the last three years I’ve built a patient-engaging capability for a large pharma organisation. So I come with that corporate, strategic background. The co-author of the book, Mitchell Silva, is a patient. He’s a patient expert himself, he’s a EUPATI scholar, and he’s built a virtual patient network for patients with cancer. So between us we bring both perspectives. We demonstrate clearly in the book why the industry needs to change, but also how it needs to change and what operating framework could be put in place that enables effective patient engagement, delivering value for both the industry as well as the patients and allied stakeholders.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
A seat at the table: what the EU HTA reforms really ask of patient involvement
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.
Why faster trials make participant understanding more important than ever
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
Older trial participants reject bad design, not technology
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.
5 key takeaways from the Patient Centricity and Engagement Conference
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.
It’s time to stop calling adverse events ‘manageable’
A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.
The value: why localisation pays off across global trials
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
The solution: Good localisation doesn’t feel translated
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.
Healthcare information is becoming easier to access. Trust isn’t.
Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.
It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment
ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.